RxDoctor Payments DataLook up a doctor →

Ian Qureshi

Hematology & Oncology · Nampa, IDNPI 1871934547

Payments from drug & device makers

$49,185in general payments, 2019–2025

Across 279 payments — averaging $176.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • G1 Therapeutics, Inc.$16K
  • Janssen Research & Development, LLC$15K
  • AstraZeneca$10K
  • Servier Pharmaceuticals LLC$2K
  • Array Biopharma Inc$658
  • E.r. Squibb & Sons, L.L.C.$472
  • plus $6K from 48 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
G1 Therapeutics, Inc.6$15,651
Janssen Research & Development, LLC27$15,140
AstraZeneca22$9,974
Servier Pharmaceuticals LLC1$1,760
Array Biopharma Inc2$658
E.r. Squibb & Sons, L.L.C.15$472
Seagen Inc.9$462
Pfizer26$455
Johnson & Johnson(2 entities)19$440
Bristol Myers Squibb10$411
Incyte Corporation7$343
Amgen5$264
Lilly USA, LLC7$227
Merck11$217
Novocure GmbH1$200
Janssen Scientific Affairs, LLC6$194
AbbVie7$179
Novartis8$170
Genentech USA, Inc.9$160
Sanofi7$144
Daiichi Sankyo Inc.6$135
Eisai Inc.7$130
Pharmacyclics LLC, An Abbvie Company5$107
Takeda Pharmaceuticals U.S.A., Inc.5$105
Bayer4$105
AVEO Pharmaceuticals, Inc.2$95
GSK5$90
Pharmaessentia USA Corporation3$80
Agios Pharmaceuticals, Inc.1$80
Genentech, Inc.2$72
Blueprint Medicines Corporation2$62
Astellas Pharma US Inc4$61
Rigel Pharmaceuticals, Inc.2$59
Tempus AI, Inc2$49
Exelixis Inc.2$37
Mirati Therapeutics, Inc.2$36
EMD Serono, Inc.2$33
Regeneron Healthcare Solutions, Inc.2$33
Boehringer Ingelheim1$24
Recordati_rare_diseases_inc.1$22
Puma Biotechnology, Inc.1$21
Adaptive Biotechnologies Corporation1$21
Dova Pharmaceuticals1$20
Acrotech Biopharma Inc.1$19
Jazz Pharmaceuticals Inc.1$19
ADC Therapeutics America, Inc.1$19
Secura Bio, Inc.1$18
Deciphera Pharmaceuticals Inc.1$18
Karyopharm Therapeutics Inc.1$17
Shield Therapeutics Inc1$17
Morphosys, US Inc.1$16
Sobi, Inc1$16
Tesaro, Inc.1$14
Beigene USA, Inc.1$12

How this compares

$49,185 in reported general payments places this provider in the 80th percentile of 34 hematology & oncology providers in Idaho.

See all hematology & oncology providers in Idaho →

Medicare billing

Part B allowed, 2024
$79,250
Medicare patients
265
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Nampa

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →